Lilly Asia Ventures

investment firm

About

Lilly Asian Ventures is an investment firm that invests in promising life science companies.

Details

Industries
Biotechnology,Pharmaceutical,Venture Capital
Founded date
Jan 1, 2008
Operating Status
Active
Also Known As
礼来亚洲基金,Lilai Yazhou Jijin
Investor Type
Venture Capital

Lilly Asian Ventures makes venture capital investments in Asia for Eli Lilly and Company, a global innovation-driven pharmaceutical company. Lilly Asian Ventures invests in promising life science companies with strong management teams and innovative technology and/or business models. Their initial focus will be primarily on opportunities in China, although they will consider investment opportunities elsewhere in east and south Asia.

Funds Raised

Announced Date Fund Name Money Raised
Feb 14, 2019 LAV Biosciences Fund V $40M
Aug 13, 2017 LAV Biosciences Fund IV $450M

Investments

Number of Investments
Number of Lead Investments
170
49
Lilly Asia Ventures has made 170 investments. Their most recent investment was on Jan 20, 2023, when ADARx Pharmaceuticals raised $46M.
Date Company Name
Round Money Raised Industry Lead Investor
Series B $46M Biotechnology
Dec 21, 2022 Ronovo Surgical
Series B Health Care
Dec 9, 2022 LavaMed
Series A $40M Manufacturing
Series A $52M Biotechnology
Nov 11, 2022 Pulnovo Medical
Series Unknown Health Care

Employee Profiles

Number of Employee Profiles
3
Lilly Asia Ventures has 3 current employee profiles, including Executive Yi Shi
Executive
Executive
Board member

Exits

Lilly Asia Ventures has had 38 exits. Lilly Asia Ventures most notable exits include Structure Therapeutics ,   Tmunity Therapeutics

Date Company Name Exit Type Industry
Feb 2, 2023 Structure Therapeutics IPO Biotechnology Detail
Dec 20, 2022 Tmunity Therapeutics M&A Biotechnology Detail
Jul 24, 2022 InventisBio IPO Biopharma Detail
Apr 1, 2022 Remegen IPO Biotechnology Detail
Mar 29, 2022 Veritas Genetics M&A Biotechnology Detail